Parkman Healthcare Partners LLC Purchases 208,029 Shares of Silence Therapeutics plc (NASDAQ:SLN)

Parkman Healthcare Partners LLC grew its position in Silence Therapeutics plc (NASDAQ:SLN) by 71.8% during the third quarter, HoldingsChannel reports. The firm owned 497,870 shares of the company’s stock after buying an additional 208,029 shares during the period. Parkman Healthcare Partners LLC’s holdings in Silence Therapeutics were worth $9,051,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Values First Advisors Inc. bought a new position in Silence Therapeutics during the third quarter worth about $56,000. Quarry LP bought a new position in shares of Silence Therapeutics in the second quarter valued at approximately $114,000. Verition Fund Management LLC purchased a new position in Silence Therapeutics during the third quarter valued at approximately $207,000. Custom Index Systems LLC bought a new position in Silence Therapeutics in the 2nd quarter valued at $282,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Silence Therapeutics during the third quarter valued at $318,000. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Price Performance

Shares of Silence Therapeutics stock opened at $7.67 on Wednesday. Silence Therapeutics plc has a 1 year low of $5.81 and a 1 year high of $27.72. The stock has a market cap of $229.56 million, a price-to-earnings ratio of -4.89 and a beta of 1.05. The firm’s 50-day moving average is $15.63 and its two-hundred day moving average is $18.03.

Wall Street Analysts Forecast Growth

SLN has been the subject of several research reports. BMO Capital Markets reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday. Jefferies Financial Group began coverage on Silence Therapeutics in a research note on Tuesday, September 3rd. They set a “buy” rating and a $40.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, November 15th. Finally, William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $57.20.

Silence Therapeutics Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.